Can-Fite BioPharma (CANF) Competitors $1.58 +0.05 (+3.27%) (As of 12/6/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends CANF vs. PMN, DARE, INKT, RNXT, LSB, DRRX, NAII, CLDI, CERO, and EQShould you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include ProMIS Neurosciences (PMN), Daré Bioscience (DARE), MiNK Therapeutics (INKT), RenovoRx (RNXT), Lakeshore Biopharma (LSB), DURECT (DRRX), Natural Alternatives International (NAII), Calidi Biotherapeutics (CLDI), CERo Therapeutics (CERO), and Equillium (EQ). These companies are all part of the "pharmaceutical products" industry. Can-Fite BioPharma vs. ProMIS Neurosciences Daré Bioscience MiNK Therapeutics RenovoRx Lakeshore Biopharma DURECT Natural Alternatives International Calidi Biotherapeutics CERo Therapeutics Equillium Can-Fite BioPharma (NYSE:CANF) and ProMIS Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership. Is CANF or PMN more profitable? Can-Fite BioPharma's return on equity of 0.00% beat ProMIS Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Can-Fite BioPharmaN/A N/A N/A ProMIS Neurosciences N/A -636.20%-130.32% Does the MarketBeat Community believe in CANF or PMN? Can-Fite BioPharma received 3 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 8.20% of users gave Can-Fite BioPharma an outperform vote. CompanyUnderperformOutperformCan-Fite BioPharmaOutperform Votes58.20%Underperform Votes5691.80% ProMIS NeurosciencesOutperform Votes2100.00% Underperform VotesNo Votes Which has stronger earnings & valuation, CANF or PMN? Can-Fite BioPharma has higher revenue and earnings than ProMIS Neurosciences. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCan-Fite BioPharma$740K7.56-$7.63M-$1.79-0.88ProMIS Neurosciences$10K3,167.66-$13.21M-$0.10-9.69 Does the media prefer CANF or PMN? In the previous week, Can-Fite BioPharma had 2 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 2 mentions for Can-Fite BioPharma and 0 mentions for ProMIS Neurosciences. ProMIS Neurosciences' average media sentiment score of 0.00 beat Can-Fite BioPharma's score of -0.53 indicating that ProMIS Neurosciences is being referred to more favorably in the news media. Company Overall Sentiment Can-Fite BioPharma Negative ProMIS Neurosciences Neutral Do analysts recommend CANF or PMN? Can-Fite BioPharma currently has a consensus target price of $14.00, indicating a potential upside of 786.08%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Can-Fite BioPharma is more favorable than ProMIS Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33ProMIS Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of CANF or PMN? 21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 50.1% of ProMIS Neurosciences shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by insiders. Comparatively, 4.4% of ProMIS Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, CANF or PMN? Can-Fite BioPharma has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. SummaryCan-Fite BioPharma beats ProMIS Neurosciences on 12 of the 18 factors compared between the two stocks. Ad WealthPressThe indicator behind Nvidia’s rally has a new prospectEvery now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANF vs. The Competition Export to ExcelMetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$5.63M$6.76B$5.32B$20.42BDividend YieldN/A8.03%5.77%3.46%P/E Ratio-0.885.0883.8136.79Price / Sales7.56344.641,246.0818.56Price / CashN/A58.0543.1022.43Price / Book0.905.464.845.58Net Income-$7.63M$152.76M$120.54M$984.98M7 Day Performance-28.18%1.62%0.55%-0.88%1 Month Performance-22.93%-2.48%0.14%1.47%1 Year Performance-32.77%28.47%33.81%23.78% Can-Fite BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANFCan-Fite BioPharma2.2428 of 5 stars$1.58+3.3%$14.00+786.1%-27.2%$5.63M$740,000.00-0.888Analyst ForecastPMNProMIS Neurosciences1.1794 of 5 stars$0.92-1.9%N/A-15.7%$30.14M$10,000.00-9.406Gap UpDAREDaré Bioscience2.5506 of 5 stars$3.41-0.6%$24.00+603.8%-22.0%$29.67M$2.81M-5.7930Positive NewsINKTMiNK Therapeutics2.0747 of 5 stars$0.74+0.8%$6.50+779.9%-32.9%$29.22MN/A-1.8830RNXTRenovoRx1.935 of 5 stars$1.20-5.5%$6.13+410.4%+125.8%$28.80MN/A-2.216News CoveragePositive NewsGap DownLSBLakeshore Biopharma0.2987 of 5 stars$3.09+12.4%N/AN/A$28.76M$573.42M0.00773Gap DownDRRXDURECT2.9024 of 5 stars$0.92+4.5%$5.00+443.5%+20.8%$28.56M$8.55M-1.5080Analyst ForecastNAIINatural Alternatives International0.3324 of 5 stars$4.57-2.6%N/A-30.0%$28.33M$113.80M-3.26290Analyst ForecastPositive NewsGap DownCLDICalidi Biotherapeutics2.6818 of 5 stars$2.14+0.9%$16.67+678.8%N/A$27.99M$50,000.000.0041CEROCERo TherapeuticsN/A$0.17-9.6%N/AN/A$26.23MN/A0.008Gap DownEQEquillium2.0581 of 5 stars$0.73-2.4%$5.00+581.8%+20.9%$25.98M$45.91M-5.3640 Related Companies and Tools Related Companies ProMIS Neurosciences Alternatives Daré Bioscience Alternatives MiNK Therapeutics Alternatives RenovoRx Alternatives Lakeshore Biopharma Alternatives DURECT Alternatives Natural Alternatives International Alternatives Calidi Biotherapeutics Alternatives CERo Therapeutics Alternatives Equillium Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CANF) was last updated on 12/7/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CANF Stock Alerts